References
- . Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med. 2009;169(6):572–578
- . United States Census Bureau. American fact finder. Available at http://factfinder.census.gov/servlet/STTable?_bm=y&-qr_name=ACS_2007_1YR_G00_S0101&-geo_id=01000US&-ds_name=ACS_20071_YR_G00_&-state=st&-_lang=en&-redoLog=false. Accessed June 30, 2009
- . Rader D, Hobbs H. Disorders of lipoprotein metabolism. In: Fauci A, Braunwald E, Kasper D, Hauser S, , eds. Harrison's Principles of Internal Medicine. 17th ed. New York, NY; McGraw-Hill; 2008
- . Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol. 2006;98(4A):71i–76i
- . Cianflone K, Paglialunga S, Roy C. Intestinally derived lipids: metabolic regulation and consequences—an overview. Atheroscler Suppl. 2008;9(2):63–68
- . Knopp RH, Paramsothy P, Atkinson B, . Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. Am J Cardiol. 2008;101(8A):48B–57B
- . Pejic R, Lee D. Hypertriglyceridemia. J Am Board Fam Med. 2006;19(3):310–316
- . Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451(7181):904–913
- . Bays H. Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians. Drugs Today (Barc). 2008;44(3):205–246
- . American Heart Association. Fish and omega-3 fatty acids. 2009. Available at http://www.americanheart.org/presenter.jhtml?identifier=4632. Accessed March 3, 2009
- . Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ. 2007;176(8):1113–1120
- . American Diabetes Association. Winning at work—diabetes facts. Available at http://www.diabetes.org/communityprograms-and-localevents/waw-diabetes-facts.jsp. Accessed March 4, 2009
- . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002;106(25):3143–3421
- . Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486–2497
- . Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes. J Cardiovasc Pharmacol. 2008;51(4):331–351
- . Newcomer JW. Metabolic risk during antipsychotic treatment. Clin Ther. 2004;26(12):1936–1946
- . Austin M, Hokanson J, Edwards K. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12B
- . United States Department of Agriculture. Agriculture fact book 2001-2002: profiling food consumption in America. http://www.usda.gov/factbook/chapter2.htm. Accessed June 1, 2009
- . American Heart Association. Statistical fact sheet—overweight and obesity—statistics. 2009. http:www.americanheart.org/presenter;jhtml?identifier=4639. Accessed March 5, 2009
- . Aguilar-Salinas CA, Delgado A, Gomez-Perez FJ. The advantages of using non–HDL-C in the diagnosis and treatment of dyslipidemia. Arch Intern Med. 2002;162(1):108–109
- . GlaxoSmithKline. LOVAZA Prescribing Information. Research Triangle Park, NC; 2008
- . Oh RC, Lanier JB. Management of hypertriglyceridemia. Am Fam Physician. 2007;75(9):1365–1371
- . Food and Drug Administration. FDA news: FDA Announces qualified health claims for omega-3 fatty acids. 2004. Available at http://www.fda.gov/bbs/topics/news/2004/NEW01115.html. Accessed March 6, 2009
- . Harris WS, Rothrock DW, Fanning A, . Fish oils in hypertriglyceridemia: a dose-response study. Am J Clin Nut. 1990;51(3):399–406
- . Harris WS. Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res. 1989;30(6):785–807
- . Kris-Etherton PM, Hill AM. N-3 fatty acids: food or supplements? J Am Diet Assoc. 2008;108(7):1125–1130
- . Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EG. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis. 2008;197(1):12–24
- . Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98(4A):27i–33i
- . Food and Drug Administration. Overview of dietary supplements. Available at http://www.fda.gov/Food/DietarySupplements/ConsumerInformation/ucm110417.htm#regulate. Accessed June 20, 2009
- . Harris WS, Ginsberg HN, Arunakul N, . Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385–391
- . Pownall HJ, Brauchi D, Kilinc C, . Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143(2):285–297
- . Brunton S, Collins N. Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr Med Res Opin. 2007;23(5):1139–1145
- . Statement on a Nonproprietary Name Adopted by the USAN Council: Omega-3-acid Ethyl Esters; Omacor/K85. United States Approved Name. Available at http://www.ama-ssn.org/ama1/pub/upload/mm/365/omega_3_acid.doc. Accessed March 23, 2009